acc1001 |
S6 |
phosphorylation |
Ser235 |
human |
Pancreas Cancer |
PANC-1 |
Metformin |
Associated |
4.0 |
23437362
|
acc1002 |
S6 |
phosphorylation |
Ser236 |
human |
Pancreas Cancer |
PANC-1 |
Metformin |
Associated |
4.0 |
23437362
|
acc1003 |
AKT |
phosphorylation |
Ser473 |
human |
Prostate Cancer |
LNCaP-Bic |
Sorafenib |
Associated |
4.0 |
22383427
|
acc1004 |
AKT |
phosphorylation |
Ser473 |
human |
Prostate Cancer |
PC3-DR |
Sorafenib |
Associated |
4.0 |
22383427
|
acc1005 |
ERK1 |
phosphorylation |
Thr202 |
human |
Leukemia |
HL-60 |
Arachidonic acid(AA) + TPA |
Associated |
3.0 |
23490067
|
acc1006 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Leukemia |
HL-60 |
Arachidonic acid(AA) + TPA |
Associated |
3.0 |
23490067
|
acc1007 |
ERK2 |
phosphorylation |
Thr185 |
human |
Leukemia |
HL-60 |
Arachidonic acid(AA) + TPA |
Associated |
3.0 |
23490067
|
acc1008 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Leukemia |
HL-60 |
Arachidonic acid(AA) + TPA |
Associated |
3.0 |
23490067
|
acc1009 |
ERK1 |
phosphorylation |
Thr202 |
human |
Lung Cancer |
U1752 |
Erlotinib |
Impairing |
5.0 |
23923067
|
acc1010 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Lung Cancer |
U1752 |
Erlotinib |
Impairing |
5.0 |
23923067
|
acc1011 |
ERK2 |
phosphorylation |
Thr185 |
human |
Lung Cancer |
NCI-H292 |
Erlotinib |
Impairing |
5.0 |
23923067
|
acc1012 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Lung Cancer |
NCI-H292 |
Erlotinib |
Impairing |
5.0 |
23923067
|
acc1013 |
AKT |
phosphorylation |
Ser473 |
human |
Lung Cancer |
U1752 |
Erlotinib |
Impairing |
5.0 |
23923067
|
acc1014 |
AKT |
phosphorylation |
Ser473 |
human |
Lung Cancer |
Calu-6 |
Erlotinib |
Impairing |
5.0 |
23923067
|
acc1015 |
AKT |
phosphorylation |
Ser473 |
human |
Lung Cancer |
NCI-H292 |
Erlotinib |
Impairing |
5.0 |
23923067
|
acc1016 |
ERK2 |
phosphorylation |
Thr185 |
human |
Lung Cancer |
U1752 |
Erlotinib |
Impairing |
5.0 |
23923067
|
acc1017 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Lung Cancer |
U1752 |
Erlotinib |
Impairing |
5.0 |
23923067
|
acc1018 |
ERK1 |
phosphorylation |
Thr202 |
human |
Lung Cancer |
Calu-6 |
Erlotinib |
Impairing |
5.0 |
23923067
|
acc1019 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Lung Cancer |
Calu-6 |
Erlotinib |
Impairing |
5.0 |
23923067
|
acc1020 |
ERK2 |
phosphorylation |
Thr185 |
human |
Lung Cancer |
Calu-6 |
Erlotinib |
Impairing |
5.0 |
23923067
|
acc1021 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Lung Cancer |
Calu-6 |
Erlotinib |
Impairing |
5.0 |
23923067
|
acc1022 |
ERK1 |
phosphorylation |
Thr202 |
human |
Lung Cancer |
NCI-H292 |
Erlotinib |
Impairing |
5.0 |
23923067
|
acc1023 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Lung Cancer |
NCI-H292 |
Erlotinib |
Impairing |
5.0 |
23923067
|
acc1024 |
AKT |
phosphorylation |
Ser473 |
human |
Lung Cancer |
PC9 |
Erlotinib |
Impairing |
5.0 |
23872583
|
acc1025 |
AKT |
phosphorylation |
Ser473 |
human |
Lung Cancer |
11月18日 |
Erlotinib |
Impairing |
5.0 |
23872583
|
acc1026 |
Src |
phosphorylation |
Tyr416 |
human |
Lung Cancer |
PC9 |
Erlotinib |
Impairing |
5.0 |
23872583
|
acc1027 |
Src |
phosphorylation |
Tyr416 |
human |
Lung Cancer |
11月18日 |
Erlotinib |
Impairing |
5.0 |
23872583
|
acc1028 |
beta-catenin |
phosphorylation |
Ser33 |
human |
Hepatocellular Carcinoma |
SMMC-7721 |
Esculetin |
Associated |
4.0 |
28789402
|
acc1029 |
beta-catenin |
phosphorylation |
Ser37 |
human |
Hepatocellular Carcinoma |
SMMC-7721 |
Esculetin |
Associated |
4.0 |
28789402
|
acc1030 |
beta-catenin |
phosphorylation |
Thr41 |
human |
Hepatocellular Carcinoma |
SMMC-7721 |
Esculetin |
Associated |
4.0 |
28789402
|
acc1031 |
AKT |
phosphorylation |
Ser473 |
human |
Bladder Cancer |
SQ20B |
Radiation |
Impairing |
4.5 |
16166302
|
acc1032 |
AKT |
phosphorylation |
Ser473 |
human |
Bladder Cancer |
T24 |
Radiation |
Impairing |
4.5 |
16166302
|
acc1033 |
AKT |
phosphorylation |
Ser473 |
human |
Breast Cancer |
MCF7 |
Estradiol |
Associated |
4.0 |
17138652
|
acc1034 |
ErbB2 |
phosphorylation |
Tyr1248 |
human |
Breast Cancer |
MCF7 |
AG826 |
Associated |
4.0 |
17138652
|
acc1035 |
ErbB2 |
phosphorylation |
Tyr1248 |
human |
Breast Cancer |
MCF7 |
AG826 |
Associated |
4.0 |
17138652
|
acc1036 |
AKT |
phosphorylation |
Ser473 |
human |
Esophageal Cancer |
TE1 |
Eupatilin |
Associated |
4.0 |
29693162
|
acc1037 |
ERK1 |
phosphorylation |
Thr202 |
human |
Esophageal Cancer |
TE1 |
Eupatilin |
Associated |
4.0 |
29693162
|
acc1038 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Esophageal Cancer |
TE1 |
Eupatilin |
Associated |
4.0 |
29693162
|
acc1039 |
ERK2 |
phosphorylation |
Thr185 |
human |
Esophageal Cancer |
TE1 |
Eupatilin |
Associated |
4.0 |
29693162
|
acc1040 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Esophageal Cancer |
TE1 |
Eupatilin |
Associated |
4.0 |
29693162
|
acc1041 |
Akt |
phosphorylation |
Ser473 |
rat |
Pituitary Tumor |
MMQ |
Everolimus + Cabergoline |
Associated |
4.0 |
35721701
|
acc1042 |
AKT |
phosphorylation |
Ser473 |
human |
Pituitary Tumor |
NF-PitNET |
Everolimus + Cabergoline |
Associated |
4.0 |
35721701
|
acc1043 |
Akt |
phosphorylation |
Ser473 |
mouse |
Melanoma |
B16F10 |
Staurosporine |
Impairing |
5.0 |
16707598
|
acc1044 |
Akt |
phosphorylation |
Ser473 |
mouse |
Melanoma |
B16F10 |
Fenofibrate |
Associated |
4.0 |
16707598
|
acc1045 |
ERalpha |
phosphorylation |
Ser118 |
human |
Endometrial Cancer |
ECC1 |
MPA |
Impairing |
5.0 |
23530112
|
acc1046 |
ERalpha |
phosphorylation |
Ser118 |
human |
Endometrial Cancer |
USPC1 |
MPA |
Impairing |
5.0 |
23530112
|
acc1047 |
ERalpha |
phosphorylation |
Ser167 |
human |
Endometrial Cancer |
ECC1 |
MPA |
Impairing |
5.0 |
23530112
|
acc1048 |
ERalpha |
phosphorylation |
Ser167 |
human |
Endometrial Cancer |
USPC1 |
MPA |
Impairing |
5.0 |
23530112
|
acc1049 |
AKT |
phosphorylation |
Ser473 |
human |
Endometrial Cancer |
ECC1 |
MPA |
Impairing |
5.0 |
23530112
|
acc1050 |
AKT |
phosphorylation |
Ser473 |
human |
Endometrial Cancer |
USPC1 |
MPA |
Impairing |
5.0 |
23530112
|